We were deterred by the cost and the time it required,” said Ribas. What tipped the scales in favor of patenting was “The peace of mind patents gave the institutions we came out of, but what we wanted was to find drug candidates,” specified the founder of Omnia.
Lo que hizo decantar la balanza a favor de patentar fue “la tranquilidad de que las patentes generaban a las instituciones de las que salíamos, pero lo que nos interesaba era encontrar candidatos a fármacos” ha puntualizado el fundador de Omnia.